Canutillo High grad overcomes severe injuries, on track for career now
He was hit by a semitruck and suffered severe injuries.
Johnson, now age 20 and a 2023 graduate of Canutillo High School, basically had to relearn to walk, eat, basically how to live, his mother Ana said.
'It was like he had to be reborn,' Ana Johnson said.
But through a special needs program at Canutillo High School, Johnson is now on track for a full-time job and a rewarding future career as a pharmacy technician.
'It's a beacon of hope,' Cash Johnson said, in his soft-spoken, understated way.
Dina Thompson, a biotechnical science teacher at Canutillo High School, taught Johnson before and after he was hurt.
'It is a beautiful story of resilience, of faith and hard work, ' she said.
During the past year, Johnson has returned to Canutillo High, which he can do as a special needs student, and has participated in the national and international job training program Project Search.
Johnson has become the first Project Search student in the nation to earn a training license to become a pharmacy technician, his teachers said.
He will take a state test in May to become certified as a pharmacy tech.
Project Search at Canutillo High is affiliated with The Hospitals of Providence Transmountain Campus and Johnson went through a year's worth of training and education there.
After he passes his state certification test in May, he is hoping to go back to the hospital and work there full time.
Johnson said he likes dealing with numbers and organization, and those things make pharmacy work perfect for him.
Erin McNellis, the Project Search teacher at Canutillo High, said that Johnson has grown in amazing ways as a person over the past few years.
'He is responsible. He is much more mature,' McNellis said. 'He is ready to go out and get things done and go out and conquer the world.'
The Project Search Program follows the same calendar as the school year, McNellis said.
During the program, students go through three 10-week sessions in different parts of the hospital.
For Johnson, his program was tailored to meet his interest in the pharmacy.
Johnson said he has been fascinated by pharmacies since he was a young boy and now his dream of working at one is within sight.
He also credits Dr. Roberto Guevara, pharmacy director at the hospital, calling him an amazing teacher and mentor.
Cash's mother, Ana Johnson, said the Project Search program has been a godsend for her son and her family.
'Every single parent, we all worry when we have children,' Ana Johnson said. 'We worry about their future. Just imagine having a kid with disabilities. Your worry is twice.'
She said that the Project Search team at Canutillo High has been there for her son, but also for her when she needed encouragement or a hug, too.
'I am so grateful for Canutillo Independent School District for its special needs program,' Ana Johnson said. 'There will be more Cashes. More kids getting jobs through Project Search and why not, going to college too – going to college which is the plan for my son. Hopefully, he will do it.
'More than anything, it has been these beautiful ladies (here at Canutillo High),' Ana Johnson said. 'They have been there from day one. If it wasn't for them, he wouldn't be here (having this success).'
Brenda Matamoros is the transition specialist at Canutillo ISD.
She said that Johnson was part of the inaugural Project Search class at Canutillo High and will serve as a 'role model' for future students in the program.
'I believe he is a shining star for the rest of the students, for what Project Search is capable of, with hard work and determination,' Matamoros said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
3 days ago
- New York Post
New pretzel-shaped device cured 82% of bladder cancer patients — most in just 3 months
There's a new twist in the fight against bladder cancer — and it's delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs directly into the bladder eliminated tumors in 82% of patients whose cancer had resisted standard treatment. For most, the cancer vanished within three months, and nearly half remained disease-free a year later. Advertisement 3 Johnson & Johnson is the manufacture of TAR-200, an experimental device for the treatment of bladder cancer. MIT Koch Institute / Instagram Dr. Sia Daneshmand, director of urologic oncology with Keck Medicine of USC and lead author of a study, said called the finding a 'breakthrough' in how certain types of bladder cancer might be treated. Each year, more than 80,000 people in the US are diagnosed with bladder cancer. The most common type is non-muscle-invasive, where the disease remains in the bladder's lining and hasn't reached the muscle layer. When features like high-grade tumors increase the chances of recurrence or progression, it's classified as high-risk. Advertisement For these patients, treatment often involves the immunotherapy drug Bacillus Calmette-Guérin (BCG). Delivered through a catheter into the bladder, it typically stays in place for a few hours, stimulating the body's immune system to attack cancer cells. But BCG isn't effective for everyone. Studies show that up to 40% of patients either don't respond initially or see their cancer return. That's meant treatment progressed to removing the bladder and surrounding tissue and organs. To offer a less invasive alternative, researchers developed the TAR-200. Advertisement Like BCG, this small, pretzel-shaped device is inserted into the bladder via catheter, where it slowly releases the chemotherapy drug gemcitabine over three weeks per treatment cycle. 3 Bladder cancer affects an organ in the lower abdomen that stores urine. shidlovski – 'The theory behind this study was that the longer the medicine sits inside the bladder, the more deeply it would penetrate the bladder and the more cancer it would destroy,' said Daneshmand, who has been researching the treatment since 2016. Advertisement It worked. Daneshmand's team treated 85 patients with high-risk non-muscle-invasive bladder cancer who had relapsed after BCG therapy. In 70 of the 85 patients, the cancer disappeared. For almost half the participants, was still gone a year later. That's significant, because patients often relapse within a year of standard treatment, and many become unresponsive to further therapies. The most common side effects were mild urinary symptoms — like frequent urination, burning, urgency and urinary tract infections — which usually resolved within weeks. 3 TAR-200 delivers a targeted, slow release of gemcitabine directly into the bladder. Bernard Chantal – 'This new therapy is the most effective one reported to date for the most common form of bladder cancer,' said Daneshmand. Several clinical trials are currently underway exploring TAR-200, made by Johnson & Johnson, and its slow-release delivery of chemotherapy into the bladder. In July, the FDA granted it priority review status, aiming to complete the review within six months instead of the usual 10. Advertisement 'TAR-200 represents an innovation in drug delivery that has not been seen in decades,' Dr. Yusri Elsayed, global therapeutic area head of oncology at Johnson & Johnson Innovative Medicine, said earlier this summer. 'The FDA Priority Review for TAR-200 underscores our mission to fundamentally change the way urologists treat certain types of bladder cancer.' Bladder cancer ranks as the 10th leading cause of death in the US, with an estimated 17,420 deaths expected in 2025, according to the American Cancer Society. The disease is more common in men than women, though incidence rates have declined by about 1% annually for both sexes in recent years. This drop is likely linked to decreased smoking rates, the leading risk factor for bladder cancer.
Chicago Tribune
4 days ago
- Chicago Tribune
The silent disease that's been killing Americans for decades — And what doctors are doing about it
Heart disease remains the leading cause of death in the U.S., claiming a life every 34 seconds. But beyond heart attacks or other sudden events, a quieter threat is building inside Americans' blood vessels. It's called arterial calcification, an often overlooked driver of serious health complications. Now a breakthrough technology offers hope for better treatment. When arteries become narrowed or hardened due to the buildup of plaque, it's known as atherosclerosis. Over time, these plaques can calcify, meaning they harden into rigid, rocklike deposits that line the inner or middle walls of arteries. This process, called calcification, makes arteries less flexible and more likely to get blocked, raising the risk of heart attacks, strokes and limb loss. Peripheral artery disease is a common result of this process. It happens when narrowed or hardened arteries reduce blood flow to the legs and feet. PAD affects approximately 230 million people worldwide, yet many don't realize it. Arterial calcification can also affect the arteries that supply the heart, leading to coronary artery disease. When blood flow to the heart is restricted, it can cause chest pain, shortness of breath and heart attacks. Annually, the disease results in 17.8 million deaths worldwide. Like PAD, CAD develops silently over time. Once identified, calcified plaques are notoriously hard to treat. Standard procedures can work well for soft plaque. Doctors thread a tiny balloon into the blocked artery, inflate it to compress the blockage, then often insert a metal mesh tube called a stent to keep the vessel open. With calcified arteries, rigid calcium often doesn't budge. Traditional balloons may fail to expand or cause artery tears. Similarly, stents may not fully deploy, increasing procedural complications. In short, older tools try to push through the problem. But next-generation technology uses a different approach: preparing the artery first, helping ensure procedures are safer and more efficient. Enter intravascular lithotripsy, a breakthrough therapy that borrows from an unexpected source: kidney stone treatment. For decades, doctors have used sound waves to break up kidney stones through a minimally invasive procedure. IVL applies the same principle inside the artery, delivering controlled sonic pulses through a modified balloon catheter to gently crack calcium deposits from within. This approach avoids many complications of more aggressive procedures and is considered one of the most promising developments in interventional cardiology. IVL was first approved for coronary use just four years ago, with adoption growing rapidly. One early IVL company quickly became the market leader and was acquired by Johnson & Johnson in 2024 — another sign of the technology's growing importance in cardiovascular Medical is a standout innovator in the IVL space, pushing the boundaries of energy delivery and procedural efficiency to elevate outcomes in peripheral and coronary interventions. 'FastWave Medical's novel IVL platforms offer genuine promise for addressing severely calcified coronary arteries that are difficult to traverse,' says Dr. Kathleen Kearney, medical director of the Cardiac Cath Lab at UWMC Montlake. 'These technological improvements are greatly needed to empower physicians in providing more effective treatment to their patients.' But what makes FastWave particularly noteworthy isn't just its technology; it's who's backing it. Alongside venture investors, physicians — cardiologists, vascular surgeons and interventional radiologists — have invested in the company. Their involvement signals more than financial interest; it reflects confidence in the system's potential to address the daily challenges they face in the cath lab. When physicians invest in medical technology, it demonstrates something powerful: They believe it will genuinely improve their ability to deliver high-quality care. 'FastWave is moving quickly and decisively to become best-in-class in the IVL space,' said Dr. Arthur Lee, director of peripheral vascular services at the Cardiac and Vascular Institute. 'We are excited to support the development of this groundbreaking technology and get it into the hands of those who need it most.' 'Calcified arteries remain one of the most difficult conditions to treat in our field,' added Dr. Amir Kaki, director of mechanical circulatory support and high-risk coronary interventions at Henry Ford St. John Hospital. 'FastWave's IVL platform is a compelling advancement that should provide a more precise, efficient and predictable way to manage complex arterial disease.' As of July 2025, the company holds a total of eight patents, with several more applications underway. These patents span key areas of the technology from energy delivery to catheter design. Early study results are encouraging for the company's dual IVL platforms. In June, FastWave successfully completed initial first-in-human procedures as part of an ongoing feasibility study for its coronary laser-based IVL system. An Investigational Device Exemption is also planned to evaluate its electric IVL system for the treatment of PAD. 'Calcified lesions aren't just a technical challenge — the condition remains one of the most significant barriers to successful peripheral interventions,' said Dr. Sahil Parikh, director of endovascular services at Columbia University Irving Medical Center. 'FastWave's upcoming IDE trial for PAD will give us a chance to assess whether an advanced IVL system can meaningfully improve the lives of patients who suffer from this difficult disease.' Dr. Venita Chandra, clinical professor of surgery at Stanford Health Care, expects the trial to reveal whether FastWave's device will offer doctors a better tool for difficult cases. 'The key question isn't just whether a device works but whether it makes procedures more efficient and provides physicians with a more predictable tool for treating patients with complex arterial disease,' she said. The stakes are rising rapidly. As the population ages and rates of diabetes and obesity continue to climb, more patients will face PAD and CAD. For the most difficult cases, treatment options are quite limited. But innovation is catching up. First-generation IVL introduced a new treatment paradigm; now advanced tools from startups like FastWave promise doctors more ways to treat this disease.
Business Upturn
09-08-2025
- Business Upturn
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:
